Here’s a startling fact: Women with early-stage, low-grade endometrial cancer who skip hysterectomy face significantly higher risks of death—not just from cancer, but also from cardiovascular disease and other causes. But here’s where it gets controversial: These risks are especially pronounced among racial and ethnic minorities or those at age extremes, raising questions about equity in cancer care. Let’s break it down.
In a recent cohort study published in O&G Open, researchers examined 27,331 patients with grade 1, stage IA endometrioid adenocarcinoma. Of these, 98.7% underwent hysterectomy, while a small fraction (1.3%) did not. The standard treatment for this condition typically includes hysterectomy with bilateral salpingo-oophorectomy and lymph node evaluation, boasting a 5-year survival rate of 95%. However, some patients—those wishing to preserve fertility or deemed medically inoperable—opt for medical management, often with progestin-based therapy, delaying surgery until after childbearing. And this is the part most people miss: The long-term outcomes for those who avoid surgery have been largely understudied—until now.
The study revealed striking disparities. Among younger patients (18-49 years), non-Hispanic White women were least likely to forgo hysterectomy (2.8%), compared to Hispanic (4.9%), Asian or Pacific Islander (4.0%), and Black patients (8.2%). The most common reason for avoiding surgery? Clinicians simply didn’t recommend it (42.1%). Over a median follow-up of four years, endometrial cancer deaths were rare overall (0.8%), but the differences were stark: those who skipped surgery had significantly higher mortality rates across the board. Specifically, they faced a 4.2% risk of endometrial cancer-related death (vs. 1.2% in the surgery group), a 7.8% risk of cardiovascular disease death (vs. 2.1%), and a 23% all-cause mortality rate (vs. 8.2%).
Here’s the bold question: Are these disparities a reflection of patient choice, systemic biases in healthcare, or something else entirely? The study doesn’t provide definitive answers, but it does underscore the critical need for personalized, equitable care in endometrial cancer treatment. For now, the data is clear: avoiding surgery in this population comes with heightened risks. But as we navigate these findings, let’s also consider the broader implications for healthcare access, patient autonomy, and the role of cultural or socioeconomic factors in treatment decisions. What’s your take? Share your thoughts in the comments—this conversation is far from over.
